ResMed Director Peter Farrell Plans Further Insider Share Sale Under Rule 144

The latest announcement is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).

ResMed director Peter C. Farrell has filed a notice to sell 2,000 shares of the company’s common stock under Rule 144, with Merrill Lynch acting as broker and the trade expected to occur on the New York Stock Exchange on April 1, 2026. The planned sale follows a series of similar 2,000‑share disposals in January, February, and March 2026, and is being conducted under a Rule 10b5‑1 trading plan adopted in August 2025, signaling ongoing, prearranged insider share sales rather than a sudden change in sentiment.

Farrell acquired the shares through stock option exercises paid in cash, and he has certified that he is not aware of any undisclosed adverse information regarding ResMed’s current or prospective operations. For investors, the filing highlights continued insider diversification but does not, on its face, indicate operational concerns at the company.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$36.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. is a medical technology company that develops and manufactures devices and software for the diagnosis, treatment, and management of sleep-disordered breathing and other chronic respiratory conditions. The company focuses on sleep apnea therapies and cloud-connected solutions for patients, providers, and home-care services worldwide.

Average Trading Volume: 1,201,111

Technical Sentiment Signal: Hold

Current Market Cap: A$47.33B

See more data about RMD stock on TipRanks’ Stock Analysis page.